Table 1.

Baseline characteristics of the patients included in the analysis.

	Missing data (N)	BLV (n=114)	BLV+Peg-IFN (n=69)	p value∗
Clinical characteristics
Age†, years		42 [35–51]	42 [36–51]	0.8
Female‡		37 (32)	23 (33)	0.9
BMI†, kg/m2	26	25.1 [22.3–27.6]	24.5 [22.5–28.2]	0.8
HIV‡	2	21 (19)	8 (12)	0.2
Liver stiffness measurement (FibroScan®)†, kPa	64	12 [9–19]	11 [8–17]	0.3
Cirrhosis‡		83 (73)	52 (75)	0.7
Platelets†, per cm3	5	144 [83–196]	163 [122–230]	0.01
Co-medication with NUC‡		97 (85)	51 (74)	0.06
Viral and biochemical characteristics
HBeAg-negative‡	35	74 (85)	56 (92)	0.2
HDV RNA† (log10 IU/ml)		6.5 [5.3–6.9]	6.7 [5.5–7.3]	0.3
Undetectable HBV DNA‡	15	88 (81)	36 (60)	0.03
HBsAg† (log10 IU/ml)	111	3.7 [2.9–4.1]	3.7 [3.4–4.1]	0.5
ALT† (IU/L)	3	78 [51.8–119]	84 [54.5–143]	0.5
Follow up†, days		335 [273–358]	341 [331–331]	0.2

ALT, alanine transaminase; BLV, bulevirtide; NUC, nucleos(t)ide analogs; Peg-IFN, pegylated interferon.

^∗Wilcoxon test; Pearson’s test.

^†Median [IQR].

^‡n (%).